Fremanezumab in the Prevention of High-Frequency Episodic and Chronic Migraine: A 12-Week, Multicenter, Real-Life, Cohort Study (The FRIEND Study).Piero Barbanti, Fabrizio Vernieri, Maria Albanese et al.|Research Square|2021Cited by 6
Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 studyPiero Barbanti, Alfonso Coppola, Gabriella Egeo et al.|The Journal of Headache and Pain|2026Cited by 0